Dubai’s GluCare.Health rebrands as Metabolic to tackle interconnected health conditions

UAE—GluCare.Health, a UAE-based healthcare company founded in 2020, has rebranded as Metabolic to reflect its expanded mission beyond diabetes care.

The transformation positions the company as a comprehensive metabolic health platform that uses technology and continuous monitoring to identify risk factors early and coordinate treatment across multiple interconnected conditions.

The rebrand responds to growing scientific understanding that metabolic syndrome functions as a multi-system condition rather than isolated diseases.

Experts now recognize that shared risk factors drive outcomes across diabetes, pre-diabetes, obesity, polycystic ovary syndrome (PCOS), fatty liver disease, chronic kidney disease, cardiovascular disease, and chronic inflammation.

Metabolic’s approach acknowledges that managing these conditions requires continuous measurement and integrated care pathways rather than occasional doctor visits.

The Metabolic OS Platform

The company’s core offering, Metabolic OS, operates as a hybrid care system connecting advanced diagnostics, remote monitoring, and artificial intelligence-enabled decision support into a unified, clinician-led service.

The platform emphasizes that AI serves as a force multiplier when embedded into clinical workflows and supported by experienced multidisciplinary teams rather than functioning as a standalone solution.

“Over five years we’ve built what we wish the healthcare system had from day one: an operating system for metabolic risk,” said Ali Hashemi, CEO and co-founder.

He explained that the platform integrates data, signals, and actions into measurable outcomes rather than functioning as disconnected apps and tests.

“AI is most powerful when it supports great clinicians and helps patients stay engaged between visits,” Hashemi added.

Addressing regional health challenges

Dr. Ihsan Almarzooqi, Managing Director and Co-Founder, highlighted that a significant proportion of people with type 2 diabetes in the UAE remain uncontrolled, while the same metabolic drivers fuel obesity, cardiovascular disease, fatty liver disease, and hormonal disorders.

“The clinical need is clear: earlier detection, better risk stratification, and longitudinal support,” he said.

“The technology now exists to do this well, but only if it’s integrated into a coordinated care model.”

Expanded services and clinical results

While diabetes management remains central, Metabolic now offers services spanning endocrinology, cardiology, thyroid disorders, women’s health, men’s health, obesity management, preventive health, sleep disorders, osteoporosis, and ophthalmology.

The platform provides a 360-degree patient view across biomarkers, imaging, vitals, and lifestyle signals.

Real-world publications in 2025 reported substantial improvements among patients, including HbA1c reductions of up to 2.3 percentage points, approximately 10% weight loss within three months, 15% reductions in waist circumference, 30% lower triglycerides, and 12% reductions in systolic blood pressure.

The company also documented improved muscle preservation for patients using GLP-1 therapies.

GluCare.Health will continue as Metabolic’s research and insights division. Headquartered in Dubai, the company plans UK clinic launches in 2026 and US expansion in 2027.